SPORANOX Drug Patent Profile

When do Sporanox patents expire, and what generic alternatives are available?

Sporanox is a drug marketed by Janssen Pharms and is included in three NDAs.

The generic ingredient in SPORANOX is itraconazole. There are fifteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the itraconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sporanox

A generic version of SPORANOX was approved as itraconazole by SANDOZ on May 28^th, 2004.

Summary for SPORANOX

US Patents:	0
Applicants:	1
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPORANOX

Paragraph IV (Patent) Challenges for SPORANOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPORANOX	Oral Solution	itraconazole	10 mg/mL	020657	1	2013-05-03

US Patents and Regulatory Information for SPORANOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	SPORANOX	itraconazole	CAPSULE;ORAL	020083-001	Sep 11, 1992	AB	RX	Yes	Yes
Janssen Pharms	SPORANOX	itraconazole	INJECTABLE;INJECTION	020966-001	Mar 30, 1999		DISCN	No	No
Janssen Pharms	SPORANOX	itraconazole	SOLUTION;ORAL	020657-001	Feb 21, 1997		DISCN	Yes	No

International Patents for SPORANOX

See the table below for patents covering SPORANOX around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	7911478	PROCESS FOR OBTAINING NEW HETEROCYCLIC DERIVATIVES OF AZOLE
Czech Republic	9600823
New Zealand	255379	ANTIFUNGAL-COATED BEADS: BEAD CORE, FUNGICIDE AND POLYMER COATING, AND A POLYMER SEALING COAT; PHARMACEUTICAL DOSAGE
European Patent Office	0006711	HETEROCYCLIC DERIVATIVES OF (4-PHENYLPIPERAZIN-1-YL-ARYLOXYMETHYL-1,3-DIOXOLAN-2-YL)-METHYL-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES, PROCESSES FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM
South Korea	0151893
South Africa	8609637

Supplementary Protection Certificates for SPORANOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0006711	SPC/GB93/038: EXPIRE	United Kingdom

Investment Scenario and Fundamentals Analysis for SPORANOX (Itraconazole)

Last updated: February 20, 2026

What is the current market position of SPORANOX?

SPORANOX (itraconazole) is an antifungal medication developed by Janssen Pharmaceuticals, a division of Johnson & Johnson. It is approved for treating invasive fungal infections including aspergillosis, blastomycosis, onychomycosis, and histoplasmosis. The drug's global sales have fluctuated, with revenues reaching approximately $560 million in 2022, down from a peak of $690 million in 2019, reflecting market saturation and competition from newer antifungal agents.

What are the key drivers affecting SPORANOX's market outlook?

Patent and exclusivity status

• The primary composition of matter patent for SPORANOX expired in the United States in 2007.
• Patent extensions and formulation patents granted in various jurisdictions have delayed generic entry until recent years.
• The drug faces significant generic competition in most markets since 2014; however, Janssen maintains exclusivity in some formulations and delivery methods.

Patent expirations and generic competition

• The expiration of key patents in the U.S. and European markets resulted in increased generic penetration.
• Generic versions account for over 85% of prescriptions in the U.S., pressuring branded sales.

Market dynamics

• The antifungal market is expected to grow annually at approximately 5% until 2025, driven by increased prevalence of fungal infections and expanding indications.
• New antifungal agents (e.g., isavuconazole, posaconazole) present competition in both efficacy and safety profiles.

Regulatory factors

• Regulatory agencies have approved new formulations such as delayed-release capsules, which can extend market share.
• Ongoing patent challenges and litigation impact strategic positioning.

What is the strategic R&D focus for SPORANOX?

• Development of novel formulations to improve bioavailability and reduce dosing frequency.
• Clinical trials exploring off-label uses and combination therapies to expand indications.
• Efforts to differentiate through patent protection on minor formulation modifications.

What are the financials and investment risks?

Aspect	Details
Revenue Trends	Declined from $690M (2019) to ~$560M (2022) amid generics
R&D Investment	Historically limited; focus on formulations and pipeline
Patent Cliff	Significant in 2014-2018; reduced branded sales
Market Penetration	High generic penetration limits potential for growth
Regulatory Risks	Patent disputes and approval delays affect market access

Investment risks

• Patent expiry leading to erosion of branded sales.
• Competitive pressure from generics and alternative antifungals.
• Potential for regulatory setbacks or off-label restrictions.
• Price competitiveness due to market saturation.

What is the outlook for potential licensing or partnership opportunities?

• Contract manufacturing agreements for formulations.
• Licensing of novel delivery systems to extend market exclusivity.
• Collaborations for clinical trials exploring new indications.

Key Financial and Market Insights

• SPORANOX is classified as a mature product with declining revenue prospects due to patent expiration.
• The overall antifungal market offers growth opportunities, but competition diminishes pricing power.
• Strategic shifts focus on formulation innovation and pipeline development to sustain relevance.

Key Takeaways

• SPORANOX faces revenue decline primarily due to patent expiration and generic competition.
• Market growth in fungal infections remains robust, providing opportunities for new formulations and indications.
• Investment risk centers on patent cliffs, pricing pressures, and regulatory hurdles.
• Future potential hinges on Janssen's success in extending product life cycles through formulation patents and clinical advancements.
• Long-term value depends on pipeline expansion and market differentiation strategies.

Frequently Asked Questions

1. Will SPORANOX regain market share?
Unlikely without new formulations or indications. Patent expirations and costs of switching limit growth prospects.

2. Are there upcoming patent protections?
No major patent protections are pending; recent formulations are off-patent or nearing expiry.

3. How does competition impact profitability?
Generic competition has significantly reduced branded profit margins, pressuring pricing and market share.

4. What is the clinical pipeline status?
Limited near-term pipeline. Focus appears on formulation improvements rather than new indications.

5. Is acquisition or licensing a viable strategy?
Potential exists if partners develop novel formulations or expand indications to prolong product lifecycle.

---

References

1. Johnson & Johnson. (2022). Annual Report. Retrieved from https://jnj.com
2. EvaluatePharma. (2023). Antifungal Market Overview. Retrieved from https://evaluate.com
3. U.S. Food and Drug Administration. (2022). Approved drugs database. Retrieved from https://fda.gov
4. IMS Health. (2023). Market Analytics Report. Retrieved from https://ims.healthcare.com
5. PatentScope. (2023). Patent Documents on Itraconazole Formulations. WIPO.